AB-3028
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Key Facts
About Arsenal Biosciences
Arsenal Biosciences is a private, clinical-stage biotechnology company founded in 2019 and headquartered in South San Francisco, California. The company is developing next-generation, programmable T cell therapies for solid tumors, leveraging a proprietary technology platform that integrates synthetic biology and computational tools. ArsenalBio has established a strategic multi-program collaboration with Bristol Myers Squibb and is advancing a wholly owned pipeline, with its lead candidate, AB-3028 for prostate cancer, anticipated to enter First-in-Human trials in the first half of 2026. The company is led by a seasoned team with deep expertise in cell therapy, oncology, and company building.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |